Amgen Inc. (NASDAQ:AMGN) Shares Sold by Thomasville National Bank

Thomasville National Bank trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 12.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,030 shares of the medical research company’s stock after selling 417 shares during the quarter. Thomasville National Bank’s holdings in Amgen were worth $790,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brookstone Capital Management boosted its holdings in Amgen by 8.2% in the fourth quarter. Brookstone Capital Management now owns 19,252 shares of the medical research company’s stock valued at $5,018,000 after purchasing an additional 1,462 shares in the last quarter. Trust Co. of Toledo NA OH boosted its holdings in Amgen by 8.6% in the fourth quarter. Trust Co. of Toledo NA OH now owns 29,527 shares of the medical research company’s stock valued at $7,696,000 after purchasing an additional 2,340 shares in the last quarter. Fiduciary Alliance LLC boosted its holdings in shares of Amgen by 8.3% in the fourth quarter. Fiduciary Alliance LLC now owns 28,906 shares of the medical research company’s stock valued at $7,534,000 after acquiring an additional 2,222 shares during the period. Winthrop Advisory Group LLC boosted its holdings in shares of Amgen by 22.5% in the fourth quarter. Winthrop Advisory Group LLC now owns 839 shares of the medical research company’s stock valued at $219,000 after acquiring an additional 154 shares during the period. Finally, TT International Asset Management LTD acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $951,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.7 %

Shares of NASDAQ:AMGN traded up $4.52 during mid-day trading on Monday, hitting $266.75. 910,158 shares of the company traded hands, compared to its average volume of 2,729,015. The firm has a market cap of $143.39 billion, a P/E ratio of 34.15, a PEG ratio of 2.91 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm’s 50 day simple moving average is $279.10 and its 200 day simple moving average is $308.66.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the business earned $4.96 EPS. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.57%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 121.90%.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Leerink Partners decreased their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Wells Fargo & Company cut their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler cut their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Finally, UBS Group dropped their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average target price of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.